THE ROLE OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 AND CYSTATIN C IN THE PATHOGENESIS AND DIAGNOSIS OF DIFFERENT FORMS OF GUILLAIN-BARRÉ SYNDROME
Keywords:
Guillain-Barré syndrome, monocyte chemoattractant protein-1, cystatin C, demyelinating polyneuropathy (AIDP), axonal forms (AMSAN, AMAN), biomarkersAbstract
Guillain-Barré syndrome (GBS) is an acute inflammatory polyneuropathy characterized by demyelination and axonal damage of peripheral nerves. This study examines the levels of monocyte chemoattractant protein-1 (MCP-1) and cystatin C in patients with different clinical forms of GBS. The results showed a significant increase in MCP-1 and cystatin C levels in patients with acute motor-sensory axonal neuropathy (AMSAN) compared to other forms. These findings suggest the role of these biomarkers in the pathogenesis of GBS and their potential diagnostic value.
References
Hughes, R. A., et al. "Guillain-Barré syndrome." The Lancet. 2014.
Willison, H. J., et al. "Guillain-Barré syndrome." Nature Reviews Disease Primers. 2016.
Van den Berg, B., et al. "Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome." The Lancet Neurology. 2014.
Yuki, N., et al. "Guillain-Barré syndrome and Campylobacter jejuni infection: insights from molecular mimicry." Journal of Neuroimmunology. 2012.
Zhang, H. L., et al. "Biomarkers in Guillain-Barré syndrome: a review." Journal of Neuroimmunology. 2020.
Koska, J., et al. "Cystatin C in neurological diseases: a review." Journal of Neuroscience Research. 2019.
Kieseier, B. C., et al. "The role of chemokines in inflammatory neuropathies." Journal of the Peripheral Nervous System. 2018.
Uncini, A., et al. "Electrodiagnostic criteria for Guillain-Barré syndrome: a critical revision and update." Clinical Neurophysiology. 2017.
